Many therapeutic drugs are racemates ; i.e . they are chiral molecules consisting of “left”- and “right-handed” enantiomers (stereoisomers that are mirror images of each other, and are non-superimposable). In some cases, both enantiomers of the drug contribute to some extent (or equally) to the therapeutic effect ; in other cases they contribute not at all. The same is true for the adverse effects of racemate drugs: the adverse effects of a racemate drug can be greater-than, less-than, or equal to one or the other enantiomer. An unusual situation arises when a drug consists of “atropisomers”, stereoisomers arising because of hindered rotation about a single chemical bond. We summarize the concept of atropisomerism, and give examples.
Christie, G.H. and Kenner, J. (1922) LXXI.—The Molecular Configurations of Polynuclear Aromatic Compounds. Part I. The Resolution of γ-6:6’-Dinitro- and 4:6:4’:’6’-Tetranitro-Diphenic Acids into Optically Active Components. Journal of the Chemical Society, Transactions, 121, 614-620. https://doi.org/10.1039/CT9222100614
Wube, A.A., et al. (2006) Knipholone, a Selective Inhibitor of Leukotriene Metabolism. Phytomedicine, 13, 452-456. https://doi.org/10.1016/j.phymed.2005.01.012
Pfeiffer, R.R. (1981) Structural Features of Vancomycin. Reviews of Infectious Diseases, 3, S205-S209. https://doi.org/10.1093/clinids/3.Supplement_2.S205
Brooks, W.H., Guida, W.C. and Daniel, K.G. (2011) The Significance of Chirality in Drug Design and Development. Current Topics in Medicinal Chemistry, 11, 760-770. https://doi.org/10.2174/156802611795165098
Nguyen, L.A., He, H. and Pham-Huy, C. (2006) Chiral Drugs: An Overview. International Journal of Biomedical Science, 2, 85-100.
McConathy, J. and Owens, M.J. (2003) Stereochemistry in Drug Action. The Primary Care Companion to The Journal of Clinical Psychiatry, 5, 70-73. https://doi.org/10.4088/PCC.v05n0202
Ariëns, E.J. (1991) Racemic Therapeutics—Ethical and Regulatory Aspects. European Journal of Clinical Pharmacology, 41, 89-93. https://doi.org/10.1007/BF00265897
Geisslinger, G., Menzel-Soglowek, S., Beck, W.S. and Brune, K. (1993) R-Flurbiprofen: Isomeric Ballast or Active Entity of the Racemic Compound? Agents and Actions Supplements, 44, 31-36.
Raffa, R.B., et al. (1992) Opioid and Nonopioid Components Independently Contribute to the Mechanism of Action of Tramadol, an ‘Atypical’ Opioid Analgesic. Journal of Pharmacology and Experimental Therapeutics, 260, 275-285.
Raffa, R.B., et al. (1993) Complementary and Synergistic Antinociceptive Interaction between the Enantiomers of Tramadol. Journal of Pharmacology and Experimental Therapeutics, 267, 331-340.
Grond, S., Meuser, T., Zech, D., Hennig, U. and Lehmann, K.A. (1995) Analgesic Efficacy and Safety of Tramadol Enantiomers in Comparison with the Racemate: A Randomised, Double-Blind Study with Gynaecological Patients Using Intravenous Patient-Controlled Analgesia. Pain, 62, 313-320. https://doi.org/10.1016/0304-3959(94)00274-I
Carcu-Dobrin, M., et al. (2017) Enantioselective Analysis of Fluoxetine in Pharmaceutical Formulations by Capillary Zone Electrophoresis. Saudi Pharmaceutical Journal, 25, 397-403. https://doi.org/10.1016/j.jsps.2016.09.007
Kim, J., Riggs, K.W. and Rurak, D.W. (2004) Stereoselective Pharmacokinetics of Fluoxetine and Norfluoxetine Enantiomers in Pregnant Sheep. Drug Metabolism & Disposition, 32, 212-221.
DeVane, C.L. and Boulton, D.W. (2002) Great Expectations in Stereochemistry: Focus on Antidepressants. CNS Spectrums, 7, 28-33. https://doi.org/10.1017/S1092852900028571
Tokunaga, E., Yamamoto, T., Ito, E. and Shibata, N. (2018) Understanding the Thalidomide Chirality in Biological Processes by the Self-Disproportionation of Enantiomers. Scientific Reports, 8, 17131. https://doi.org/10.1038/s41598-018-35457-6
Mori, T., et al. (2018) Structural Basis of Thalidomide Enantiomer Binding to Cereblon. Scientific Reports, 8, 1294. https://doi.org/10.1038/s41598-018-19202-7
Vargesson, N. (2015) Thalidomide-Induced Teratogenesis: History and Mechanisms. Birth Defects Research Part C: Embryo Today: Reviews, 105, 140-156. https://doi.org/10.1002/bdrc.21096
Toenjes, S.T. and Gustafson, J.L. (2018) Atropisomerism in Medicinal Chemistry: Challenges and Opportunities. Future Medicinal Chemistry, 10, 409-422. https://doi.org/10.4155/fmc-2017-0152
Welch, C.J., et al. (2009) Factors Influencing the Interconversion of a New Class of Dibenzodiazepine Sulfonamide Atropisomers. Chirality, 21, E105-E109. https://doi.org/10.1002/chir.20785
Nguyen, T. (2018) Giving Atropisomers Another Chance. Chemical & Engineering News, 96, 22-25. https://doi.org/10.1021/cen-09633-feature1
Beutner, G., et al. (2018) Adventures in Atropisomerism: Total Synthesis of a Complex Active Pharmaceutical Ingredient with Two Chirality Axes. Organic Letters, 20, 3736-3740. https://doi.org/10.1021/acs.orglett.8b01218
Bai, H.Y., et al. (2019) Highly Atroposelective Synthesis of Nonbiaryl Naphthalene-1,2-Diamine N-C Atropisomers through Direct Enantioselective C-H Amination. Nature Communications, 10, 3063. https://doi.org/10.1038/s41467-019-10858-x
Bonne, D. and Rodriguez, J. (2017) Enantioselective Syntheses of Atropisomers Featuring a Five-Membered Ring. Chemical Communications, 53, 12385-12393. https://doi.org/10.1039/C7CC06863H
Wencel-Delord, J., Panossian, A., Leroux, F.R. and Colobert, F. (2015) Recent Advances and New Concepts for the Synthesis of Axially Stereoenriched Biaryls. Chemical Society Reviews, 44, 3418-3430. https://doi.org/10.1039/C5CS00012B
LaPlante, S.R., Edwards, P.J., Fader, L.D., Jakalian, A. and Hucke, O. (2011) Revealing Atropisomer Axial Chirality in Drug Discovery. ChemMedChem, 6, 505-513. https://doi.org/10.1002/cmdc.201000485
Laplante, S.R., et al. (2011) Assessing Atropisomer Axial Chirality in Drug Discovery and Development. Journal of Medicinal Chemistry, 54, 7005-7022. https://doi.org/10.1021/jm200584g
Takahashi, H., et al. (2011) Atropisomerism Observed in Indometacin Derivatives. Organic Letters, 13, 760-763. https://doi.org/10.1021/ol103008d
Yu, F.H. and Catterall, W.A. (2003) Overview of the Voltage-Gated Sodium Channel Family. Genome Biology, 4, 207. https://doi.org/10.1186/gb-2003-4-3-207
Catterall, W.A., Goldin, A.L. and Waxman, S.G. (2005) International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels. Pharmacological Reviews, 57, 397-409. https://doi.org/10.1124/pr.57.4.4
Lampert, A., Dib-Hajj, S.D., Tyrrell, L. and Waxman, S.G. (2006) Size Matters: Erythromelalgia Mutation S241T in NaV1.7 Alters Channel Gating. The Journal of Biological Chemistry, 281, 36029-36035. https://doi.org/10.1074/jbc.M607637200
Fertleman, C.R., et al. (2006) SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes. Neuron, 52, 767-774. https://doi.org/10.1016/j.neuron.2006.10.006
Han, C., et al. (2012) NaV1.7-Related Small Fiber Neuropathy: Impaired Slow-Inac- tivation and DRG Neuron Hyperexcitability. Neurology, 78, 1635-1643. https://doi.org/10.1212/WNL.0b013e3182574f12
Cox, J.J., et al. (2006) An SCN9A Channelopathy Causes Congenital Inability to Experience Pain. Nature, 444, 894-898. https://doi.org/10.1038/nature05413
Goncalves, T.C., Benoit, E., Partiseti, M. and Servent, D. (2018) Corrigendum: The NaV1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons. Frontiers in Pharmacology, 9, 1241. https://doi.org/10.3389/fphar.2018.01241
Goncalves, T.C., Benoit, E., Partiseti, M. and Servent, D. (2018) The NaV1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons. Frontiers in Pharmacology, 9, 1000. https://doi.org/10.3389/fphar.2018.01000
Hameed, S. (2019) NaV1.7 and Nav1.8: Role in the Pathophysiology of Pain. Molecular Pain, 15. https://doi.org/10.1177/1744806919858801
Tanaka, B.S., et al. (2017) Gain-of-Function Mutation of a Voltage-Gated Sodium Channel NaV1.7 Associated with Peripheral Pain and Impaired Limb Development. The Journal of Biological Chemistry, 292, 9262-9272. https://doi.org/10.1074/jbc.M117.778779
Meents, J.E., et al. (2019) The Role of NaV1.7 in Human Nociceptors: Insights from Human Induced Pluripotent Stem Cell-Derived Sensory Neurons of Erythromelalgia Patients. Pain, 160, 1327-1341. https://doi.org/10.1097/j.pain.0000000000001511
Weiss, M.M., et al. (2017) Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. Journal of Medicinal Chemistry, 60, 5969-5989. https://doi.org/10.1021/acs.jmedchem.6b01851
Graceffa, R.F., et al. (2017) Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. Journal of Medicinal Chemistry, 60, 5990-6017. https://doi.org/10.1021/acs.jmedchem.6b01850
Kornecook, T.J., et al. (2017) Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7. Journal of Pharmacology and Experimental Therapeutics, 362, 146-160. https://doi.org/10.1124/jpet.116.239590